Research programme: immune checkpoint anticancer therapies - Shire/Symphogen

Drug Profile

Research programme: immune checkpoint anticancer therapies - Shire/Symphogen

Alternative Names: Immune checkpoint therapies - Shire/Symphogen

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxalta; Symphogen
  • Developer Shire; Symphogen
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Checkpoint kinase inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 04 Jan 2016 Baxalta and Symphogen agree to co-develop Immune checkpoint therapies for Cancer
  • 04 Jan 2016 Early research in Cancer in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top